Summary
This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this in patients with ovarian cancer who receive paclitaxel/carboplatin chemotherapy after primary surgery.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Clinical diagnose and histology of invasive epithelial ovarian/tuba or peritoneal cancer * FIGO stage IIb-IV any grade or FIGO Ia-IIa only grade 3 or clear cell carcinoma (any stage and grade) * Natural candidate for paclitaxel 175mg/m2 + Carboplatin (AUC=5-6) * Baseline CA125≥70 AND/OR evaluable disease after RECIST (incl ultrasound) * 18 years or older * Caucasian (ie.parents and grandparents are Caucasian) * Performance status 2 or lower (after WHO/ECOG) Exclusion Criteria: * Prior malignant disease apart from cervical carcinoma in situ and basal cell carcinoma of the skin * Prior chemo / radiotherapy * Ongoing or imminent other chemotherapies * Pregnant or lactating * Fertile woman of childbearing potential not willing to use adequate contraception * Neurological symptoms (any kind) worse than CTCAE grade 1 * Active infection or other serious disease that could impair on treatment and/or follow-up